Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Acumen Pharmaceuticals, Inc. (ABOS) had Stock-Based Compensation of $9.85M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-25.14M |
|
-- |
|
-- |
|
$25.20M |
|
$-25.20M |
|
$0.06M |
|
$-25.14M |
|
$-25.14M |
|
$-25.14M |
|
$-25.14M |
|
$-25.14M |
|
$-25.14M |
|
$-25.20M |
|
$-25.04M |
|
60.56M |
|
60.56M |
|
$-0.40 |
|
$-0.40 |
|
| Balance Sheet Financials | |
$122.25M |
|
-- |
|
$0.58M |
|
$122.83M |
|
$30.01M |
|
$22.40M |
|
$22.40M |
|
$52.40M |
|
$70.43M |
|
$70.43M |
|
$70.43M |
|
60.58M |
|
| Cash Flow Statement Financials | |
$-115.54M |
|
$133.93M |
|
$-0.03M |
|
$35.86M |
|
$54.22M |
|
$18.36M |
|
|
Stock-Based Compensation |
$9.85M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.07 |
|
-- |
|
-- |
|
0.24 |
|
0.44 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-115.63M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-35.69% |
|
-35.69% |
|
-20.47% |
|
-27.08% |
|
$1.16 |
|
$-1.91 |
|
$-1.91 |
|